740873-06-7

Usage

Uses

Used in Pharmaceutical Industry:
N-[3-[4-[4-[(Cyclohexylmethylsulfonyl)amino]butyl]piperazin-1-yl]phenyl]acetamide is used as a potential drug candidate for its potential therapeutic applications. Its complex structure and functional groups may allow it to interact with biological systems in ways that could be beneficial for treating various diseases or conditions. The specific use and effectiveness would be determined through further research and clinical trials.
Used in Medicinal Chemistry Research:
N-[3-[4-[4-[(Cyclohexylmethylsulfonyl)amino]butyl]piperazin-1-yl]phenyl]acetamide serves as a subject of study in medicinal chemistry, where researchers investigate its properties, interactions with biological systems, and potential applications in drug development. Its complex structure provides a basis for understanding how similar compounds may behave and contribute to the discovery of new therapeutic agents.

Upstream product

• 99-09-2 3-nitro-aniline 
• 54054-85-2 1-(3-nitrophenyl)piperazine 
• 740873-04-5 C-cyclohexyl-N-{4-[4-(3-nitrophenyl)piperazin-1-yl]butyl}methanesulfonamide 
• 740873-01-2 {4-[4-(3-nitrophenyl)piperazin-1-yl]butyl}carbamic acid tert-butyl ester 
• 740873-05-6 N-{4-[4-(3-aminophenyl)piperazin-1-yl]butyl}-C-cyclohexylmethanesulfonamide 
• 75-36-5 acetyl chloride 

Relevant academic research and scientific papers

An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression

We report the discovery of a novel, potent, and selective amidosulfonamide nonazapirone 5-HT1A agonist for the treatment of anxiety and depression, which is now in Phase III clinical trials for generalized anxiety disorder (GAD). The discovery of 20m (PRX-00023), N-{3-[4-(4- cyclohexylmethanesulfonylaminobutyl)-piperazin-1-yl]phenyl}acetamide, and its backup compounds, followed a new paradigm, driving the entire discovery process with in silico methods and seamlessly integrating computational chemistry with medicinal chemistry, which led to a very rapid discovery timeline. The program reached clinical trials within less than 2 years from initiation, spending less than 6 months in lead optimization with only 31 compounds synthesized. In this paper we detail the entire discovery process, which started with modeling the 3D structure of 5-HT1A using the PREDICT methodology, and then performing in silico screening on that structure leading to the discovery of a 1 nM lead compound (8). The lead compound was optimized following a strategy devised based on in silico 3D models and realized through an in silico-driven optimization process, rapidly overcoming selectivity issues (affinity to 5-HT1A vs α1-adrenergic receptor) and potential cardiovascular issues (hERG binding), leading to a clinical compound. Finally we report key in vivo preclinical and Phase I clinical data for 20m tolerability, pharmacokinetics, and pharmacodynamics and show that these favorable results are a direct outcome of the properties that were ascribed to the compound during the rational structure-based discovery process. We believe that this is one of the first examples for a Phase III drug candidate that was discovered and optimized, from start to finish, using in silico model-based methods as the primary tool.

NEW ARYLPIPERAZINYL COMPOUNDS

The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by formula (I), and synthesis and uses thereof for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.